• Leukemias, lymphomas, and other hematologic cancers

Idarubicin Generic Name & Formulations

General Description

Idarubicin HCl 1mg/mL; soln for IV infusion.

Pharmacological Class


See Also

How Supplied

Single-dose vials—contact supplier; PFS: Single-dose vials (5mL, 10mL, 20mL)—1

Idarubicin Indications


Acute myeloid leukemia, in combination with other antileukemic drugs.

Idarubicin Dosage and Administration


Give by slow IV infusion (over 10–15mins). 12mg/m2 daily for 3 days (in combination with cytarabine). May give 2nd course if needed; if toxicity develops after 1st course, delay until resolved; reduce dose by 25%. Hepatic and renal impairment: consider reduce dose.


Not established.

Idarubicin Contraindications

Not Applicable

Idarubicin Boxed Warnings

Boxed Warning

Extravasation. Myocardial toxicity. Severe myelosuppression. Hepatic or renal impairment.

Idarubicin Warnings/Precautions


Administer under the supervision of an experienced physician. Avoid in pre-existing bone marrow suppression. Increased risk of myocardial toxicity in pre-existing cardiovascular disease, previous anthracycline therapy at high cumulative doses, concomitant or previous mediastinal pericardial irradiation, anemia, bone marrow suppression, infections, leukemic pericarditis and/or myocarditis. Monitor CBCs, cardiac, hepatic and renal function prior to and during treatment. Monitor for hyperuricemia, infections. Hepatic or renal impairment (see Adult). Avoid extravasation. Elderly. Pregnancy: avoid. Advise to use effective contraception during and for 6.5 months (females of reproductive potential) or for 3.5 months (males w. female partners) after the last dose. Nursing mothers: not recommended (during and for 14 days after the last dose).

Idarubicin Pharmacokinetics

See Literature

Idarubicin Interactions


Concomitant drugs that suppress cardiac contractility or cardiotoxic drugs (eg, trastuzumab, cyclophosphamide, paclitaxel): not recommended; avoid use for at least 5 half-lives after discontinuing cardiotoxic drug (up to 7mos for trastuzumab).

Idarubicin Adverse Reactions

Adverse Reactions

Myelosuppression (may be severe), GI upset, mucositis, abdominal pain, alopecia, rash, inj site reactions, cardiotoxicity (eg, CHF, arrhythmias, chest pain, MI, asymptomatic declines in LVEF).

Idarubicin Clinical Trials

See Literature

Idarubicin Note

Not Applicable

Idarubicin Patient Counseling

See Literature